Nuclide Therapeutics raises €5.7 million in a seed round led by Marathon Beteiligungs AG to develop drugs targeting treatment-resistant cancers.
Amount Raised
€5.7 Million
Round Type
Seed
LondonBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
Nuclide Therapeutics, a spinout from King's College London, has closed a seed funding round of €5.7 million led by Marathon Beteiligungs AG. The company aims to create radioactive drugs for treating therapy-resistant cancers. Their technology focuses on targeting specific cell pathways linked to drug resistance. This approach aims to improve the efficacy of cancer treatment by delivering targeted therapy directly to resistant cells.
Quick answer
Nuclide Therapeutics raised €5.7 Million in a Seed round, dated September 22, 2025. Investors: Marathon Beteiligungs AG. Nuclide Therapeutics is based in London, England, United Kingdom.
- How much did Nuclide Therapeutics raise?
- Nuclide Therapeutics raised €5.7 Million in a Seed round on September 22, 2025.
- Who invested in Nuclide Therapeutics?
- Marathon Beteiligungs AG is named as investors in this round.
- What does Nuclide Therapeutics do?
- Nuclide Therapeutics is a King’s College London spinout developing radioactive drugs to target therapy-resistant cancers.
- Where is Nuclide Therapeutics based and how big is it?
- Nuclide Therapeutics is based in London, England, United Kingdom. Fundz records about 4 employees.
- Who are the decision-makers at Nuclide Therapeutics?
- Fundz holds 1 contact at Nuclide Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Nuclide Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Faeth Therapeutics raised $25M (Funding Round) on October 20, 2025.
- Aerska raised $21M (Seed) on October 1, 2025.
- Mati Therapeutics raised $9.9M on September 30, 2025.
- MAIA Biotechnology raised $2.3M (Grant) on September 24, 2025.
- Immuneering raised $25M on August 26, 2025.
- Brainstorm Cell Therapeutics raised $155K (Convertible Note) on November 6, 2025.
Who to call at Nuclide Therapeutics, and when
A new round usually means Nuclide Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nuclide Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nuclide Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nuclide Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nuclide Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Nuclide Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.